| Literature DB >> 31245194 |
Ali Fatemi1, Madhava R Kanakamedala1, Claus Chunli Yang1, Bart Morris1, William N Duggar1, Srinivasan Vijayakumar1.
Abstract
Introduction Stereotactic radiosurgery (SRS) plans created using synthetic computed tomography (CT) images derived from magnetic resonance imaging (MRI) data may offer the advantage of inhomogeneity correction by convolution algorithms, as is done for CT-based plans. We sought to determine and validate the clinical significance and accuracy of synthetic CT images for inhomogeneity correction in MRI-only stereotactic radiosurgery plans for treatment of brain tumors. Methods In this retrospective study, data from two patients with brain metastases and one with meningioma who underwent imaging with multiple modalities and received frameless SRS treatment were analyzed. The SRS plans were generated using a convolution algorithm to account for brain inhomogeneity using CT and synthetic CT images and compared with the original clinical TMR10 plans created using MRI images. Results Synthetic CT-derived SRS plans are comparable with CT-based plans using convolution algorithm, and for some targets, based on location, they provided better coverage and a lower maximum dose. Conclusions The results suggest similar dose delivery results for CT and synthetic CT-based treatment plans. Synthetic CT plans offered a noticeable improvement in target dose coverage and a more gradual dose fall-off relative to TMR10 MRI-based plans. The major disadvantage is a slightly increased dose (by 0.37%) to nearby healthy tissue (brainstem) for synthetic CT-based plans relative to those created using clinical MRI images, which may be a problem for patients undergoing high-dose treatment.Entities:
Keywords: computed tomography (ct); convolution algorithm; inhomogeneity correction; magnetic resonance imaging (mri); stereotactic radiosurgery; synthetic ct
Year: 2019 PMID: 31245194 PMCID: PMC6559689 DOI: 10.7759/cureus.4404
Source DB: PubMed Journal: Cureus ISSN: 2168-8184
Figure 1The QUASAR MRID3D phantom used to create machine-specific distortion maps
Figure 2Representation of SRS plans for single metastasis brain tumor (orange color) at multiple planes (axial, sagittal, and coronal) in MRI images (top) using TMR (10) algorithm and synthetic CT (middle) and CT (bottom) using convolution algorithm. The 50% isodose line (cyan), 20% isodose line (purple) and 12% isodose line (green) has been demonstrated for all images and plans.
Gy = Gray; TMR = Tissue Max Ratio; CT = Computed Tomography; MRI = Magnetic Resonance Imaging ; SRS = Stereotactic Radiosurgury
Dosimetric comparison of synthetic CT- and CT-based plans using convolution and regular clinical MRI with the TMR10 algorithm
Lt = Left; Rt = Right; D100 = Dose covering 100% of target volume; D95 = Dose covering 95% of tumor volume; Min = Minimum; Max = Maximum; TMR = Tissue Maximum Ratio; MRI = Magnetic Resonance Imaging
| Patient 1 | TMR10 | ||||
| Max dose (Gy) | Min dose (Gy) | Mean dose (Gy) | D100 (Gy) | D95 (Gy) | |
| Lt Temporal | 30.88 | 15.46 | 21.46 | 15.43 | 17.1 |
| Rt Frontal | 30.9 | 14.61 | 24.25 | 14.61 | 18.7 |
| Brain stem | 5 | 0.56 | 1.41 | ||
| CT Convolution | |||||
| Max dose (Gy) | Min dose (Gy) | Mean dose (Gy) | D100 (Gy) | D95 (Gy) | |
| Lt Temporal | 29.96 | 13.13 | 20.25 | 13.1 | 16.6 |
| Rt Frontal | 30.83 | 30.83 | 19.08 | 19.03 | 20.6 |
| Brain stem | 4.3 | 0.57 | 1.42 | ||
| Synthetic CT Convolution | |||||
| Max dose (Gy) | Min dose (Gy) | Mean dose (Gy) | D100 (Gy) | D95 (Gy) | |
| Lt Temporal | 30.53 | 11.77 | 21.74 | 11.73 | 17.3 |
| Rt Frontal | 30.71 | 18.19 | 24.9 | 18.17 | 20.4 |
| Brain stem | 5.37 | 0.55 | 1.42 | ||
| Patient 2 | MRI TMR10 | ||||
| Max dose (Gy) | Min dose (Gy) | Mean dose (Gy) | D100 (Gy) | D95 (Gy) | |
| Lt Temporal | 21.2 | 16.1 | 19.2 | 16.7 | 17.8 |
| Rt Frontal 1 | 22.5 | 17.2 | 21.2 | 18 | 19.9 |
| Rt Partial 1 | 26.6 | 17.5 | 24 | 18 | 21.3 |
| Rt Partial 2 | 21.3 | 18.8 | 20.5 | 18 | 19.7 |
| Rt Frontal 2 | 21.2 | 18.1 | 20.5 | 18.9 | 19.6 |
| Rt Frontal 3 | 22.4 | 18.5 | 21.6 | 18 | 20.4 |
| Lt Frontal 1 | 21.9 | 18.8 | 21 | 18 | 20.3 |
| Rt Post-Frontal | 35 | 14.9 | 23 | 15.4 | 17.8 |
| Lt Frontal 2 | 21.2 | 18.1 | 20.5 | 18 | 19.6 |
| CT Convolution | |||||
| Max dose (Gy) | Min dose (Gy) | Mean dose (Gy) | D100 (Gy) | D95 (Gy) | |
| Lt Temporal | 21.2 | 16.1 | 19 | 16.4 | 17.7 |
| Rt Frontal 1 | 22.5 | 17.5 | 21.3 | 18 | 20.1 |
| Rt Partial 1 | 26.4 | 17.8 | 24.1 | 18 | 21.3 |
| Rt Partial 2 | 21.1 | 19 | 20.5 | 18 | 19.8 |
| Rt Frontal 2 | 21.1 | 18.8 | 20.4 | 18 | 19.7 |
| Rt Frontal 3 | 22.5 | 19 | 21.7 | 18 | 20.6 |
| Lt Frontal 1 | 21.9 | 18.9 | 21.1 | 18 | 20.4 |
| Rt Post-Frontal | 34.7 | 14.4 | 22.8 | 15.5 | 17.6 |
| Lt Frontal 2 | 21.1 | 18.4 | 20.5 | 18 | 19.7 |
| Synthetic CT Convolution | |||||
| Max dose (Gy) | Min dose (Gy) | Mean dose (Gy) | D100 (Gy) | D95 (Gy) | |
| Lt Temporal | 21.2 | 16.2 | 19.1 | 16.7 | 17.7 |
| Rt Frontal 1 | 22.5 | 17.4 | 21.3 | 18 | 20.1 |
| Rt Partial 1 | 26.4 | 17.9 | 24.1 | 18 | 21.4 |
| Rt Partial 2 | 21.1 | 18.9 | 20.5 | 18 | 19.8 |
| Rt Frontal 2 | 21.1 | 18.9 | 20.5 | 18 | 19.8 |
| Rt Frontal 3 | 22.5 | 19 | 21.8 | 18 | 20.6 |
| Lt Frontal 1 | 21.9 | 18.9 | 21.1 | 18 | 20.4 |
| Rt Post-Frontal | 34.7 | 14.2 | 22.8 | 15.4 | 17.5 |
| Lt Frontal 2 | 21.1 | 18.4 | 20.5 | 18 | 19.7 |
| Patient 3 | MRI TMR10 | ||||
| Max dose (Gy) | Min dose (Gy) | Mean dose (Gy) | D100 (Gy) | D95 (Gy) | |
| Meningioma Rt | 62.3 | 24 | 42.2 | 26.5 | 32.3 |
| CT Convolution | |||||
| Max dose (Gy) | Min dose (Gy) | Mean dose (Gy) | D100 (Gy) | D95 (Gy) | |
| Meningioma Rt | 42.8 | 14.1 | 27.8 | 17.5 | 21.9 |
| Synthetic CT Convolution | |||||
| Max dose (Gy) | Min dose (Gy) | Mean dose (Gy) | D100 (Gy) | D95 (Gy) | |
| Meningioma Rt | 62.5 | 24 | 42 | 26.2 | 32.1 |